Rhode Island RI
Biogen's 2022 outlook leaves investors wanting, shares slip
Biogen expects "minimal" revenue this year from its Alzheimer's treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immed…
